Gustavo Bracho

Summary

Affiliation: Finlay Institute
Country: Cuba

Publications

  1. doi request reprint Large-scale application of highly-diluted bacteria for Leptospirosis epidemic control
    Gustavo Bracho
    Finlay Institute, Ave 27, La Lisa, Havana City, Cuba
    Homeopathy 99:156-66. 2010
  2. pmc AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5
    Gustavo Bracho
    Department of Immunology, Finlay Institute, Havana City, Cuba
    Malar J 8:35. 2009
  3. ncbi request reprint Proteoliposome derived cochleate as novel adjuvant
    Gustavo Bracho
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-30-1. 2006
  4. ncbi request reprint Proteliposome-derived Cochleate as an immunomodulator for nasal vaccine
    Oliver Perez
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-52-3. 2006
  5. ncbi request reprint Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern
    Oliver Perez
    Immunology Department, Finlay Institute, Havana, Cuba
    Immunol Cell Biol 82:603-10. 2004
  6. ncbi request reprint Immunological evaluation of bacterial derived Cochleate and proteoliposome as mucosal adjuvants
    Judith Del Campo
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-50-1. 2006
  7. ncbi request reprint Scale up of proteoliposome derived Cochleate production
    Caridad Zayas
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-94-5. 2006
  8. ncbi request reprint Strategy for determination of an efficient Cochleate particle size
    Danay Gil
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-92-3. 2006
  9. doi request reprint Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses
    Judith Del Campo
    Immunology Department, Finlay Institute, PO Box 16017, Havana, Cuba
    Methods 49:301-8. 2009
  10. ncbi request reprint Interactions of proteoliposomes from serogroup B Neisseria meningitidis with bone marrow-derived dendritic cells and macrophages: adjuvant effects and antigen delivery
    Tamara Rodríguez
    Department of Immunology, Finlay Institute, PO Box 16017, Havana, Cuba
    Vaccine 23:1312-21. 2005

Detail Information

Publications15

  1. doi request reprint Large-scale application of highly-diluted bacteria for Leptospirosis epidemic control
    Gustavo Bracho
    Finlay Institute, Ave 27, La Lisa, Havana City, Cuba
    Homeopathy 99:156-66. 2010
    ..We report the results of a very large-scale homeoprophylaxis (HP) intervention against Leptospirosis in a dangerous epidemic situation in three provinces of Cuba in 2007...
  2. pmc AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5
    Gustavo Bracho
    Department of Immunology, Finlay Institute, Havana City, Cuba
    Malar J 8:35. 2009
    ....
  3. ncbi request reprint Proteoliposome derived cochleate as novel adjuvant
    Gustavo Bracho
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-30-1. 2006
    ..The results and the easy capability for new antigen incorporation on CS support its use as adjuvant for immunization with a large variety of pathogen derived antigens and different routes of immunization...
  4. ncbi request reprint Proteliposome-derived Cochleate as an immunomodulator for nasal vaccine
    Oliver Perez
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-52-3. 2006
    ..Thus, our results suggest that PL-derived Cochleate can be used as a promising immunomodulator and delivery system for the development of mucosal, particularly nasal vaccines...
  5. ncbi request reprint Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern
    Oliver Perez
    Immunology Department, Finlay Institute, Havana, Cuba
    Immunol Cell Biol 82:603-10. 2004
    ..In conclusion, our results support the use of PLCS as a potent Th1 adjuvant for parenteral and mucosal vaccines...
  6. ncbi request reprint Immunological evaluation of bacterial derived Cochleate and proteoliposome as mucosal adjuvants
    Judith Del Campo
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-50-1. 2006
    ..These results show that Cochleate and PL are capable of inducing both systemic and mucosal antibody responses as well as a Th1 type of immunity as evidenced by high gammaIFN and IgG2a antibody responses...
  7. ncbi request reprint Scale up of proteoliposome derived Cochleate production
    Caridad Zayas
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-94-5. 2006
    ..This work demonstrates that CFS is very efficient process to obtain Cochleate structures with a yield of more than 80% and the immunogenicity comparable to that obtained by dialysis membrane...
  8. ncbi request reprint Strategy for determination of an efficient Cochleate particle size
    Danay Gil
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-92-3. 2006
    ..The best treatment parameter for mechanical stress of the Cochleate was prolonged treatment with untrasonic low frequency waves...
  9. doi request reprint Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses
    Judith Del Campo
    Immunology Department, Finlay Institute, PO Box 16017, Havana, Cuba
    Methods 49:301-8. 2009
    ..These results support the use of AFCo1 as a potent Th1 inducing adjuvant particularly suitable for mucosal immunization...
  10. ncbi request reprint Interactions of proteoliposomes from serogroup B Neisseria meningitidis with bone marrow-derived dendritic cells and macrophages: adjuvant effects and antigen delivery
    Tamara Rodríguez
    Department of Immunology, Finlay Institute, PO Box 16017, Havana, Cuba
    Vaccine 23:1312-21. 2005
    ..The work also shows the potential of PL as a general system to deliver antigens to DC for presentation to CD4+ and CD8+ T-cells...
  11. ncbi request reprint Bacterial derived proteoliposome as ideal delivery system and cellular adjuvant
    Tamara Rodríguez
    Department of Immunology, Finlay Institute, 27 Ave, b 198 and 202 La Lisa, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-24-5. 2006
    ..PL exerts an immunomodulatory effect on DC and is a general system to deliver antigens for presentation to CD4+ and CD8+ T-cells possibly implicated in the induction CD8+ cytotoxic T lymphocytes (CTLs) responses...
  12. ncbi request reprint Bacterial derived proteoliposome for allergy vaccines
    Miriam Lastre
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-34-5. 2006
    ..The low dose was more effective than high dose. These results clearly support the potential use of PL as possible adjuvants for anti-allergic vaccines...
  13. ncbi request reprint The adjuvant potential of synthetic alkylglycerols
    Reinaldo Acevedo
    Department of Immunology, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-32-3. 2006
    ..These results indicate that synthetic AGs are effective adjuvants for the standardized antigen, Ova...
  14. pmc Standardization of Neisseria meningitidis serogroup B colorimetric serum bactericidal assay
    Tamara Rodríguez
    Department of Basic and Clinical Immunology, Finlay Institute, 27 avenue 198 and 202, La Lisa, P O Box 16017, Havana City, Cuba
    Clin Diagn Lab Immunol 9:109-14. 2002
    ..974, P < 0.01). The standardized cSBA allows easy, fast, and efficient evaluation of samples...
  15. ncbi request reprint 2nd International Workshop on Vaccine Adjuvants and Glycoconjugates, Varadero, Cuba, 11-15 April 2004
    Oliver Perez
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-1-2. 2006